The Weekly Recap 3/6/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, secure funding, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16-20).

ANEUVO

Has announced the closing of a Series C funding round of $22M led by Catcher Technology, with participation from additional new investors. The proceeds will be used to execute a commercial launch in approved markets and sales expansion, scale manufacturing and quality systems, and advance U.S. regulatory activities for the ExaStim^Ⓡ Stimulation System.

Boston Scientific

Announced that it promoted LSI Alumni Catherine Jennings, who has been with the company for more than two decades, to become its new president of Vascular Therapies, succeeding the retiring Jeff Mirviss. Jennings has held roles of increasing responsibility, particularly across peripheral vascular and peripheral interventions functions, and will now assume a position that spans several treatment areas, including intravascular lithotripsy, transcarotid artery revascularization (TCAR), and drug-eluting stents.

Carecam

Announced the signing of a Memorandum of Understanding (MoU) with walkey, a Japan-based gait technology company, to expand market access and deepen strategic collaboration by combining commercial reach, clinical networks, and complementary technology strengths. The collaboration also supports long-term global ambitions, including potential expansion into the U.S. market and pursuing scalable, evidence-based rehabilitation innovations for healthcare systems navigating aging populations and increasing rehabilitation demands.

CereVasc

Announced the first-in-human case report for the use of its eShunt^Ⓡ System to treat medically refractory idiopathic intracranial hypertension (IIH), with the cases led by Pedro Lylyk, MD, and the ENERI Medical Institute team in Buenos Aires. The report describes encouraging clinical improvements and sustained eShunt Implant patency over three years of follow-up, reinforcing the potential of the eShunt System’s minimally invasive, endovascular approach to expand treatment options for patients living with elevated intracranial pressure.

Cognito Therapeutics

Has announced the final close of its oversubscribed $105M Series C funding round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from new investors New Vintage, Apollo Health Ventures, and Benvolio Group, among others. The financing strengthens Cognito’s position as it advances toward pivotal data readout, regulatory submission, and commercial launch, while supporting continued clinical development of Spectris™, expansion of launch readiness efforts ahead of anticipated market entry in 2027, and advancement of the Spectris platform into additional neurodegenerative indications through its network of brain health collaboratories.

Corstasis Therapeutics

Has entered into a definitive agreement to be acquired by Esperion Therapeutics, strengthening Esperion’s commercial portfolio and enhancing potential long-term revenue growth. The deal, expected to close in Q2 2026, includes an upfront cash payment of $75M, royalties on worldwide Enbumyst sales, and up to $180M in potential milestone payments tied to certain commercial and regulatory achievements.

Dxcover

Has achieved CE-marking for its breakthrough liquid biopsy medical device under the European In Vitro Diagnostic Regulation (IDVR) 2017/746, validating the strength of the company’s clinical evidence, analytical performance, and quality systems. The certification provides a strong regulatory foundation, derisking its ability to scale the technology across clinical applications and supports future commercialization.

Gleamer

Announced that it was acquired by RadNet in a deal worth up to approximately $269.3M (€230M). RadNet plans to integrate Gleamer’s portfolio with DeepHealth’s clinical AI suites of solutions across breast, neuro, prostate, and thyroid, creating a comprehensive portfolio that supports screening, detection, interpretation, and follow-up across several cancer types, and extends to neurodegenerative and musculoskeletal conditions.

GT Medical Technologies

Announced the publication of prospective, multicenter Phase IV registry data evaluating clinical outcomes following surgical resection with immediate, localized GammaTile^Ⓡ radiation therapy in patients with newly diagnosed brain metastases. The study, published in the Journal of Neuro-Oncology, found 92.3% local tumor control at 12 months, 7.8% cumulative incidence of leptomeningeal disease, and 9.8% overall Grade 3 toxicity, with no cases of radiation necrosis reported.

Insightec

Announced that France has officially published national reimbursement for unilateral MR-guided focused ultrasound treatment for medication-refractory essential tremor in the Journal Officiel de la République Française. Under this new reimbursement framework, it allows hospitals across France to begin offering the company’s incisionless procedure, and takes effect immediately. 

Kneevoice

Has received FDA 510(k) clearance for its Cartilage Evaluation System, a non-invasive system that amplifies and records distinct acoustic vibrations within joints to support objective assessment of cartilage and overall joint condition. The company is strategically prioritizing initial commercialization concentrated in the knee joint, with the Cartilage Evaluation System now commercially available in the U.S.

OSSTEC

Announced the appointment of LSI Alumni Dr. Nick Pachuda to its Board of Directors and the establishment of U.S. operations led by U.S. Commercial Lead and LSI Alumni Christopher Campbell. Supported by the successful close of new funding, led by Embryo Ventures and participation from existing investors, the appointment marks a significant step in the company’s U.S. expansion strategy, emphasizing surgeon engagement, KOL network development, hospital and clinical partner onboarding, and preparation for U.S. regulatory clearance and commercial launch.

Perimeter Medical Imaging AI

Has received FDA PMA for Claire™, the first AI-enabled imaging device approved in the U.S. for intraoperative breast cancer margin assessment. The approval positions the company at the forefront of AI-enabled intraoperative imaging and marks the first commercialization of its proprietary OCT-AI platform, representing an initial step toward addressing a significantly larger global opportunity across additional cancer surgeries, biopsy procedures, and pathology applications.

Polares Medical

Has closed a $50M Series C financing round to support its heart leaflet replacement system. DC Global Ventures, Lumination Partners, existing investors, and a new strategic investor helped fund the round that the company is planning to use to advance clinical studies in the U.S., Europe, and Australia. 

Scalpel AI

Has officially launched a mobile app that extends its platform beyond the warehouse and into the field, the next step towards a connected world of surgical intelligence. With the app, reps and couriers can validate a tray against its digital twin in the field from their mobile device, with every scan verified by machine vision and AI and backed by a secure digital record.

Scripps Research

Welcomed medtech leader and LSI Alumni Joe Kiani to its Board of Directors. Kiani brings decades of experience in patient safety and public service, and has shaped patient monitoring and safety efforts while spearheading related initiatives spanning industry and philanthropy.

Shoulder Innovations

Announced the appointment of Drew Hykes to the company’s Board of Directors and as a member of the Compensation Committee. Hykes, with over 25 years of medtech experience, will look to support the company as it continues to rapidly scale adoption of its novel shoulder arthroplasty portfolio, and concurrent with the appointment, Geoff Pardo will resign as an Independent Director from the Board.

Spiro Robotics

Welcomed Sanjay Banerjee to the executive team as COO to help lead across operations, execution, and team alignment. Sanjay’s track record of strengthening cross-functional coordination and reinforcing accountability will help the company balance innovation with regulatory awareness, commercial readiness, and scalable execution.

Synergy Spine Solutions

Announced that it received FDA PMA for its Synergy Disc for 1-level indications at C3-C7. The device addresses both motion preservation and spinal alignment in a single device, and its IDE study saw the Synergy Disc achieve superiority in composite clinical success compared to the anterior cervical discectomy and fusion (ACDF) control at 24 months.

THINK Surgical

Announced the first completed cases using the TMINI^Ⓡ Miniature Robotic System with the Stryker Triathlon^Ⓡ Knee System. The robot, which now works with nine different compatible options, is on the heels of FDA 510(k) clearance for the use of TMINI with Triathlon and will continue to expand the commercialization of the integrated offering this year.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.